Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ArcticZymes Technologies Director's Dealing 2021

May 18, 2021

3538_dirs_2021-05-18_3b3dd0d4-58c6-4bb3-8305-c2072607ef56.html

Director's Dealing

Open in viewer

Opens in your device viewer

ArcticZymes Technologies ASA - Primary insider trading

ArcticZymes Technologies ASA - Primary insider trading

(Tromsø 18. May 2021) Volker Wedershoven, member of the Board of Directors, has

today sold 20.000 shares in ArcticZymes Technologies ASA at NOK 85,12 per share

Following this transactions holds Mr. Wedershoven 60.000 shares and 100.000

options in the company.

This notification is prepared in accordance with the EU Market Abuse Regulation

art. 19 and the Securities Trading Act section 5-12.

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the

development, manufacturing and commercialization of novel recombinant enzymes

for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.

Listed on the Oslo Stock Exchange since 2005 originally under the [Biotec]

ticker, as Biotec Pharmacon. The company rebranded as ArcticZymes Technologies

in 2020 under the [AZT] ticker. Its headquarters are based in Tromsø, Norway, at

the SIVA Innovation Centre.

ArcticZymes Technologies' IP and capabilities are protected via a large

portfolio of patents.

For more information, please visit the website: www.arcticzymes.com.